Open AccessThe Potential of 11C-acetate PET for Monitoring the Fatty Acid Synthesis Pathway in Tumors
Author(s) -
Laura M. DeFord-Watts,
Akiva Mintz,
Steven J. Kridel
Publication year - 2013
Publication title -
current pharmaceutical biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.555
H-Index - 85
eISSN - 1873-4316
pISSN - 1389-2010
DOI - 10.2174/1389201011314030006
Subject(s) - positron emission tomography , fatty acid synthesis , fatty acid , fatty acid metabolism , lipid metabolism , enzyme , pet imaging , beta oxidation , metabolic pathway , chemistry , cancer research , biochemistry , medicine , pharmacology , nuclear medicine
Positron emission tomography (PET) is a molecular imaging modality that provides the opportunity to rapidly and non-invasively visualize tumors derived from multiple organs. In order to do so, PET utilizes radiotracers, such as ¹⁸F-FDG and ¹¹C-acetate, whose uptake coincides with altered metabolic pathways within tumors. Increased expression and activity of enzymes in the fatty acid synthesis pathway is a frequent hallmark of cancer cells. As a result, this pathway has become a prime target for therapeutic intervention. Although multiple drugs have been developed that both directly and indirectly interfere with fatty acid synthesis, an optimal means to assess their efficacy is lacking. Given that ¹¹Cacetate is directly linked to the fatty acid synthesis pathway, this probe provides a unique opportunity to monitor lipogenic tumors by PET. Herein, we review the relevance of the fatty acid synthesis pathway in cancer. Furthermore, we address the potential utility of ¹¹C-acetate PET in imaging tumors, especially those that are not FDG-avid. Last, we discuss several therapeutic interventions that could benefit from ¹¹C-acetate PET to monitor therapeutic response in patients with certain types of cancers.